

## I JORNADA SEOM EJERCICIO FÍSICO Y CÁNCER







**17 DE JUNIO DE 2024** 

Meeting Place. Paseo de la Castellana, 81. Madrid

Modelos clínicos de Investigación en ejercicio Físico y Cáncer

Ander Urruticoechea

GE**icam** 

Unidad de Gestión del Cáncer de Gipuzkoa: HU Donostia-Onkologikoa-Osakidetza



### **Disclosure Information**

Travel arrangements to meetings:

Gilead, AZ-Daychii Sankyo, Novartis









#### International guidelines

Exercise is beneficial during and after cancer treatment and hence recommended.

American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control

ALPA V PATEL!, CHRISTINE M. FREDENBECH', STEVENC, MOORE', SANDRA C. HAVES', RULE K. SELVER', KRISTIN L. CAMPRELL', KERRI WINTERS-STONE', L'VIN H. GERIGRE', STEPHANGE M. GERIGRE', NORTE I PELTON'', CRYSTA, DOSENDER', S. STEPHEN MERGER', TRESHA RUL'', KATHEN H. SCHMIEZ'',

#### Exercise, Diet, and Weight Management **During Cancer Treatment: ASCO Guideline**

Accepter A. Lighter, MD1: Kari Borbic, BcD1: Acce M. May, PhD1: Streen K. Cliston, MD, PhD1: Westy Dersuin Bishvefred, PhD, RD1: Boson C. Gliskhof, MD, RB5: Melinda L. Livini, PhD, MPP1: Minited Late?; Savel Mandfeld, RB7: Emoire F. Manhalf, RPL, M111: AMVey A. Mayer-Mand, MD, MP1: Cuptible A. Thomason, PhD, RD7: William A. Wass, MD, M191: "Acceptation for Attacks, Company of the Acceptance of the Accepta

# Outcomes

Cancer types

### Mainly:

- Breast cancer
- Prostate cancer

#### Strong evidence

- Anxiety
- Depressive symptoms
- Fatigue
- Quality of life
- Physical functioning
- Lymphedema

#### Moderate evidence

- Sleep
- Bone health


#### Unsufficient evidence

- Cardiotoxicity
- CIPN (neuropathy)
- Cognitive functioning
- Risk of falls
- Nausea
- Pain
- Sexual functioning
- Treatment adherence

Other cancer types

Advanced cancers

### Clical Trials.Gov



## PREFERABLE I

Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study

Authors: Anne May, Anouk Hiensch, Johanna Depenbusch, Martina Schmidt, Evelyn Monninkhof, Mireia Pelaez, Dorothea Clauss, Philipp Zimmer, Jon Belloso, Mark Trevaskis, Helene Rundqvist, Joachim Wiskemann, Jana Müller, Carlo Fremd, Renske Altena, Joanna Kufel-Grabowska, Rhode Bijlsma, Lobke van Leeuwen-Snoeks, Daan ten Bokkel-Huinink, Gabe Sonke, Bruce Mann, Prudence Francis, Gary Richardson, Wolfram Malter, Elsken van der Wall, Neil Aaronson, Elzbieta Senkus, Ander Urruticoechea, Eva Zopf, Wilhelm Bloch, Martijn Stuiver, Yvonne Wengström, Karen Steindorf

Manuscript in press: Nature Medicine

## **Acknowledgements**

Hiensch. Johanna Depenbusch. Anouk Martina Schmidt, Evelyn Monninkhof, Mireia Pelaez. Dorothea Clauss. Philipp Zimmer. Belloso, Mark Trevaskis. Helene Rundavist, Joachim Wiskemann, Jana Müller, Carlo Fremd, Renske Altena, Joanna Kufel-Grabowska, Rhode Biilsma, Lobke van Leeuwen-Snoeks. Daan ten Bokkel-Huinink. Gabe Sonke, Bruce Mann, Prudence Francis, Gary Richardson, Wolfram Malter, Elsken van der Wall, Neil Aaronson, Elzbieta Senkus, Ander Urruticoechea, Eva Zopf, Wilhelm Bloch, Martijn Stuiver, Yvonne Wengström, Karen Steindorf



#### **Participating centers**























#### In collaboration with







#### **Funded by**







This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825677; and the Australian Government (2018/GNT1170698).

physiotherapists and exercise trainers.

all treating physicians and nurses in participating hospitals;

## Introduction – effects of exercise during cancer treatment

# **Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline**

Jennifer A. Ligibel, MD¹; Kari Bohlke, ScD²; Anne M. May, PhD³; Steven K. Clinton, MD, PhD⁴; Wendy Demark-Wahnefried, PhD, RD⁵; Susan C. Gilchrist, MD, MS⁶; Melinda L. Irwin, PhD, MPH⁻; Michele Late³; Sami Mansfield, BA⁶; Timothy F. Marshall, PhD, MS¹⁰; Jeffrey A. Meyerhardt, MD, MPH¹; Cynthia A. Thomson, PhD, RD¹¹; William A. Wood, MD, MPH¹²; and Catherine M. Alfano, PhD¹³

J Clin Oncol 40:2491-2507. © 2022 by American Society of Clinical Oncology

RESULTS - Exercise during adjuvant cancer treatment leads to improvements in cardiorespiratory fitness, strength, fatigue, and other patient-reported outcomes.

RECOMMENDATION - Oncology providers should recommend regular aerobic and resistance exercise during active treatment with curative intent.


FUTURE RESEARCH - Studies are needed in ... those with metastatic disease.

## Aim – PREFERABLE-EFFECT trial

To investigate the effects of supervised and individualized exercise in patients with metastatic breast cancer on fatigue and quality of life.



## **Methods**



#### Inclusion criteria:

- Age ≥ 18 years
- Diagnosis of breast cancer stage IV
- ECOG performance status ≤ 2
- Life expectancy of ≥6 months


#### Exclusion criteria:


- Contraindication for exercise
- Unstable bone metastases
- Too physically active (>210 min/wk)





## **Methods**








## **Methods**



Informed consent, baseline measurements (T0)



PREFERABLE

Aerobic training

moderate-intensity & high-intensity interval training

Resistance Training

major lower and upper body muscles

Balance training

## **Methods - Outcomes**

#### **Primary endpoints:**

- Cancer-related physical fatigue
- Health-related QoL

#### Secondary endpoints include:

- Pain, breast cancer specific symptoms, anxiety, depression
- Polyneuropathy, sleep
- Treatment related toxicities
- Physical fitness/performance, body composition
- Biomarkers
- Physical activity
- QALYs and direct and indirect costs



- EORTC-FA-12
- EORTC-QLQ-30 summary score

Trial successful if either or both are statistically significant.\*



 Steep ramp test (maximal short exercise capacity (MSEC))

\*At 6-month post baseline, using mixed effect models adjusted for baseline and stratification factors (Bonferroni correction).



## Results – Baseline characteristics

#### Intervention group (n=178)





Age (years) 54.9 ± 11.6



Female 99.4%



Higher education degree 73.6%



Married/living together 68.0%



 $25.9 \pm 5.1$ 



Age (years) 55.9 ± 10.7



Female 99.4%



Higher education degree 76.0%



Married/living together 65.4%



 $26.6 \pm 5.3$ 



## Results – Baseline characteristics

#### Intervention group (n=178)





Age (years) 54.9 ± 11.6



Recurrent disease 65.1%



1st/2nd line treatment 75.3%




Female 99.4%

degree

73.6%



**Hr+/HER2-: 60.7%** HER2+: 23.6%





Married/living together 68.0%

Higher education



Bone metastases 65.2%



25.9 ± 5.1



Endocrine treatment >50%



Age (years) 55.9 ± 10.7



Recurrent disease 62.1%



Female 99.4%




1st/2nd line treatment 74.3%



Higher education degree 76.0%



HR+/HER2-: 59.2% HER+: 22.9%





Married/living together 65.4%



Bone metastases 69.8%



 $26.6 \pm 5.3$ 



Endocrine treatment >50%



## Results – Attendance, SAEs & physical fitness outcome



Median attendance [IQR] = 77% [48-92]

6-month post-BL: 18% discontinuation


44% due to death



**Two SAEs:** 1 wrist fracture and 1 sacral stress fracture, none related to bone metastases.





## **Results – Primary outcomes**



## Randomization group Control Group Intervention Group


## Results – QoL functional scales








## Results – Emotional fatigue and functioning









## Results - Pain and dyspnea







PREFERABLE-PERSPECTIVE

(questionnaire n=420):

Concerns that **pain** and **fatigue** worsens while exercising

(Sweegers et al. Sup. Care Can. 2023)

58%

% Scoring above clinical important threshold at baseline\*

57%

**Dyspnea** 



Pain \* Giesinger et al. J Clin Epidemiol. 2020

## **Conclusions**

- A supervised resistance and aerobic exercise intervention resulted in beneficial effects on fatigue, HRQoL, and other clinically relevant outcomes of patients with mBC.
- We recommend supervised exercise as part of supportive care regimens during palliative treatment.







































## PREFERABLE II

The effects of live-remote exercise in patients with complaints after cancer treatment

INTRODUCTION TO THE PREFERABLE II AND OUTCOMES

Prof. Dr. Anne May







## **PREFERABLE** partners























Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.

The contents of the published material are solely the responsibility of the authors and do not reflect the views of NHMRC.











health research institute



Centre for Ethics and Law





#### Co-funded by











Onkologikoa

## PREFERABLE II – effects of **live-remote** exercise





- <u>Telemedicine</u>: One broadcast center per country
- Upscaling to other countries by establishing a broadcast center there and train a limited number of trainers




## LION RCT


The primary objective of the LION RCT is to assess the (cost-)effectiveness of a personalized, **live-remote** exercise intervention for cancer survivors on

- 1) HRQOL and
- 2) the participants' main, self-reported side-effect. The four side-effects targeted in this study are:
  - fatigue,
  - perceived low physical functioning in daily life,
  - anxiety and/or depressive symptoms,
  - and Cancer Induced Peripheral Neuropathy.





Live remote supervision for all modules from cancer exercise specialists via national broadcast centers





## Food for thought



Focos de Investigación

RESEARCH Open Access

# The Trial within Cohorts (TwiCs) study design in oncology: experience and methodological reflections



Rob Kessels<sup>1</sup>, Anne M. May<sup>2\*</sup>, Miriam Koopman<sup>3</sup> and Kit C. B. Roes<sup>4</sup>


#### Abstract


A Trial within Cohorts (TwiCs) study design is a trial design that uses the infrastructure of an observational cohort study to initiate a randomized trial. Upon cohort enrollment, the participants provide consent for being randomized in future studies without being informed. Once a new treatment is available, eligible cohort participants are randomly assigned to the treatment or standard of care. Patients randomized to the treatment arm are offered the new treatment, which they can choose to refuse. Patients who refuse will receive standard of care instead. Patients randomized to the standard of care arm receive no information about the trial and continue receiving standard of care as part of the cohort study. Standard cohort measures are used for outcome comparisons. The TwiCs study design aims to overcome some issues encountered in standard Randomized Controlled Trials (RCTs). An example of an issue in standard RCTs is the slow patient accrual. A TwiCs study aims to improve this by selecting patients using a cohort and only offering the intervention to patients in the intervention arm. In oncology, the TwiCs study design has gained increasing interest during the last decade. Despite its potential advantages over RCTs, the TwiCs study design has several methodological challenges that need careful consideration when planning a TwiCs study. In this article, we focus on these challenges and reflect on them using experiences from TwiCs studies initiated in oncology. Important methodological challenges that are discussed are the timing of randomization, the issue of non-compliance (refusal) after randomization in the intervention arm, and the definition of the intention-to-treat effect in a TwiCs study and how this effect is related to its counterpart in standard RCTs.

**Keywords** Trials within Cohorts, TwiCs, Cohort multiple randomized controlled trial, Oncology, Non-compliance, Efficacy estimand

Al abrir la cohorte el paciente ingresa dando consentimiento para ser aleatorizado en estudios sin ser informado si no es necesario

#### Al abrir el estudio los pacientes son Aleatorizados










UMBREL A




Umbrella Fit Trial Gal et al. Br Ca Res Treat 2021





## Food for thought



¿> 16.000 ensayos?





Estudios de Implementación / factibilidad en nuestros sistemas sanitarios / sociales



I JORNADA SEOM EJERCICIO FÍSICO Y CÁNCER

**17 DE JUNIO DE 2024** 

Meeting Place. Paseo de la Castellana, 81. Madrid









